Skip to content
ATLAS PREP HQ
Cognitive

Adamax

Adamantane-modified N-acetyl Semax amidate (Semax-derived experimental peptide analogue)

Semax-derived nootropic research focused on BDNF signaling, neuroprotection, and cognitive performance.

Preclinical Evidence

Route

Subcutaneous in the community protocol

Common format

10 mg vial

Research focus

cognition

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Cognitive research motifCognitive

Adamax in 30 seconds

Atlas Fast Read

What it is

Adamantane-modified N-acetyl Semax amidate (Semax-derived experimental peptide analogue)

Why people care

Semax-derived nootropic research focused on BDNF signaling, neuroprotection, and cognitive performance.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

Adamax is scientifically interesting for cognition, neuroprotection, but the current case is driven mainly by cell and animal data.

Overview

What is Adamax?

Adamax is adamantane-modified N-acetyl Semax amidate (Semax-derived experimental peptide analogue). Semax-derived nootropic research focused on BDNF signaling, neuroprotection, and cognitive performance.

A newer experimental derivative of Semax created by adding an adamantane-containing modification intended to increase stability and CNS penetration. Its history is largely an extension of Russian Semax research rather than an independent clinical-development program.

Mechanism

How it works

Mechanistic claims are extrapolated mainly from Semax: modulation of BDNF/TrkB signaling, monoamine systems, and CREB-related neuroplasticity. The adamantane modification is intended to improve lipophilicity and resistance to enzymatic breakdown, but direct human pharmacology is not established.

Research areas

cognitionneuroprotectionBDNF/neuroplasticitystress resilience

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No robust peer-reviewed human clinical program for Adamax has established efficacy, dosing, pharmacokinetics, or safety. Human claims are generally extrapolated from Semax rather than demonstrated for the adamantane-modified analogue itself.

Preclinical evidence

Direct Adamax preclinical literature is limited; its rationale largely borrows from Semax neurotrophic research and from the theoretical pharmacokinetic advantages of adamantane modification.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community reference: titrate 300 → 500 → 750 → 1,000 mcg/day.

Frequency

Once daily.

Timing

Morning or early day is a practical research convention because cognitive/stimulatory effects could interfere with sleep; not clinically validated.

Route

Subcutaneous in the community protocol; Adamax has no established clinical route.

Cycle length

8–12 weeks

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; after reconstitution 2–8 °C, protected from light, preferably used within 1–2 weeks.

Monitoring

No validated laboratory-monitoring protocol. Track blood pressure, sleep, mood/anxiety, headaches, cognition, and general CBC/CMP if used in supervised research.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Systematic human safety data are limited. Reported or plausible effects include headache, dizziness, fatigue, irritability, sleep changes, nausea and injection/nasal-site irritation depending on route.

Contraindications

No validated broad contraindication profile exists. Avoid unsupervised use in pregnancy/breastfeeding, severe psychiatric instability, seizure disorders or major neurologic disease unless the research/clinical protocol specifically addresses it.

Interactions

Formal interaction studies are limited. CNS-active medicines, sedatives, stimulants, antidepressants, anxiolytics and anticonvulsants may alter or obscure effects and should be reviewed clinically.

Stacks

Common stacks

No well-supported stack is highlighted for this peptide yet.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

Adamax is scientifically interesting for cognition, neuroprotection, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Cognitive

Cognitive

Cerebrolysin

Neurotrophic peptide mixture researched for neuroprotection, neuronal recovery, and cognitive function.

Read guide

Cognitive

PE-22-28

Experimental TREK-1 antagonist peptide research focused on neuroplasticity and mood-related pathways.

Read guide

Cognitive

Pinealon

Short peptide bioregulator research focused on neuroprotection, cognition, and age-related brain function.

Read guide